MRNA Articles
Featured Articles
Read our latest stories on the people and scientific innovations making a difference in patients’ lives.
Easing the Healthcare Burden of the Seasonal Triple-demic and Pfizer’s Unwavering Commitment to Public Health
As the cooler fall and winter months approach, we prepare for the potential seasonal increase in cases of certain respiratory viruses including—COVID-19, influenza (flu), and respiratory syncytial virus (RSV). Coined a "triple-demic," the concurrent surge of these three respiratory illnesses not only threatens our individual states of health, but can also place a greater burden on healthcare systems worldwide, diverting resources away from other patients in need. In the 2022-2023 season...
Understanding Six Types of Vaccine Technologies
Ever since the first vaccine was developed in 1796 to treat smallpox,1 several different methods have been created to develop successful vaccines. Today, those methods, known as vaccine technologies, are more advanced and use the latest technology to help protect the world from preventable diseases.2Depending on the pathogen (a bacteria or virus) that is being targeted, different vaccine technologies are used to generate an effective vaccine. Just like there are multiple ways to develop a...
Albert Bourla Reflects on the One Year Anniversary of the COVID-19 Pandemic
One year. That’s how long it has been since the World Health Organization declared COVID-19 a global pandemic. Sometimes it feels like the year went by in the blink of an eye. More often, however, it feels more like five years have gone by since many of us last gathered with loved ones, went to a movie theater or grabbed coffee with colleagues at the office. But regardless of how long it has felt to each of us, I think we can all agree it has been a year defined by loss, learning and an...
Albert Bourla On Ensuring Equitable Access to COVID-19 Vaccines
We have crossed another milestone in the fight against COVID-19. I am proud to announce that Pfizer and BioNTech have signed an advanced purchase agreement with COVAX for up to 40 million doses of our COVID-19 vaccine in 2021, subject to the execution of additional agreements under the COVAX structure. Since the very beginning of our vaccine development program, Pfizer and BioNTech have been firmly committed to equitable and affordable access of COVID-19 vaccines for people around the world...
What Makes an RNA Vaccine Different From a Conventional Vaccine?
Vaccines are one of the greatest health interventions ever developed. They’ve been cited as being as important to keeping communities healthy as having access to clean water and safe sanitation.1Through scientific investment and ingenuity, today we have multiple vaccine technology platforms that have helped us control and, in some cases, eradicate many healthcare challenges such as polio, river blindness, smallpox, and COVID-19, just to name a few.In 2020, messenger RNA, or mRNA for short, was...
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits. However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer Media Contacts may only respond to calls and emails from professional journalists.